Capecitabine
- TRADE NAME: Xeloda (Roche)
- INDICATIONS: Metastatic breast or colorectal cancer, adjuvant colon cancer
- CLASS: Antimetabolite, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Fluoropyrimidine
- HALF-LIFE: 0.5–1 hour
Allopurinol, Anticoagulants, CYP2C9 substrates, Erlotinib, Leucovorin, Phenprocoumon, Phenytoin, Tegafur/Gimeracil/Oteracil, Tegafur/Gimeracil/Oteracil, Warfarin
PREGNANCY CATEGORY: D
Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulants such as warfarin and phenprocoumon should have their anticoagulant response (INR or prothrombin time) monitored frequently in order to adjust the anticoagulant dose accordingly. Altered coagulation parameters and/or bleeding, including death, have been reported during concomitant use.
Contra-indicated in patients with severe renal impairment or with known hypersensitivity to fluorouracil.
Capecitabine is a prodrug of 5-fluorouracil.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of capecitabine in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/29/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric